An improved notch-forming tab enables a blister card package comprising a medicament to be easily opened by a user. The blister card package includes a container sheet having a well formed therein; a cover sheet laminated to the container sheet and spanning the well to form a blister containing the medicament between the cover sheet and the container sheet; and a plurality of slits defining a pattern comprising a pair of legs having respective converging and diverging ends disposed adjacent the blister. The converging ends of the pair of legs are separated from one another by between about 0.1 mm and about 1 mm and are spaced from the blister. The diverging ends of the pair of legs are spaced from an adjacent edge of the blister pack. Methods of opening this and other inventive blister card packages are also described herein.
B65D 75/32 - Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
The present invention provides an anhydrous sunscreen composition comprising: (a) at least about 15% by weight based on the total weight of the sunscreen composition of a combination of titanium dioxide and zinc oxide, wherein the weight ratio of zinc oxide to titanium dioxide in the composition is about 0.5 to about 1.5; (b) at least about 50 % by weight based on the total weight of the sunscreen composition of a carrier oil, wherein the carrier oil comprises at least 50% by weight Helianthus Annuus (Sunflower) Seed Oil; (c) about 10% to about 20% by weight based on the total weight of the sunscreen composition a combination of Isododecane and Diisopropyl Adipate; and (d) about 2% to about 6% by weight based on the total weight of the sunscreen composition of a film former comprising triacontanyl PVP.
A61K 8/81 - Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
A61K 8/92 - Oils, fats or waxesDerivatives thereof, e.g. hydrogenation products
A61Q 17/04 - Topical preparations for affording protection against sunlight or other radiationTopical sun tanning preparations
INRIA (INSTITUT NATIONAL DE RECHERCHE EN INFORMATIQUE ET EN AUTOMATIQUE) (France)
Inventor
Stamatas, Georgios N.
Lboukili, Imane
Descombes, Xavier
Abstract
Systems and methods for improving the image quality of images of epithelial tissue structures are disclosed. The systems include training a first cycle-GAN model and a second cycle-GAN model simultaneously, where the first cycle-GAN model is trained to remove noise from an image and the second cycle-GAN model is trained to learn the structure of the image. Additional systems and methods include deploying the trained cycle-GAN model to identify an unknown image segment and/or generate a protocol for following the identified skin care treatment recommendation for an identified image segment.
A device for patient risk stratification is provided. The device may include a processor configured to perform one or more actions. The processor may receive patient data indicative of an acetaminophen overdose, a time associated with acetaminophen ingestion, and an aminotransferase (AT) product level. A metric indicative of effectiveness of an acetaminophen overdose treatment for the patient may be determined based on the patient data and a cellular simulation of liver response to an acetaminophen overdose. Prognosis information may be output based on the metric.
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 70/40 - ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
G06N 7/02 - Computing arrangements based on specific mathematical models using fuzzy logic
G06N 7/06 - Simulation on general purpose computers
G06F 9/44 - Arrangements for executing specific programs
Biomimetic, prebiotic, probiotic and postbiotic compositions and methods of use thereof are disclosed. The biomimetic, prebiotic, probiotic and postbiotic compositions may include bacteria of the genera Cutibacterium acnes (C. acnes), its culture and/or components thereof; and/or a substance that induces the growth or activity of C. acnes. The biomimetic, prebiotic, probiotic and postbiotic compositions may be used in preventing, improving and/or treating such conditions such as atopic dermatitis.
A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
Described is a ready to drink electrolyte solution comprising: Sodium from 40 to 120mg /100ml, Potassium from 50 to 100mg /100ml, Chloride from 55 to 90mg /100ml, and Dextrose from 200 to 600mg /100ml, wherein an osmolality of the ready to drink electrolyte solution is lower than or equal to 268mOsm /kg.
A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
Provided are skincare compositions comprising a retinoid; and a processed oat ingredient, and methods of using same. Also provided are methods increasing CRABP2 expression in skin cells, the method comprising topically applying to skin a skincare composition comprising a processed oat ingredient.
Provided are skincare compositions comprising: a compound having retinol-like activity and a processed oat ingredient. Also provided are methods for treating skin comprising topically applying these compositions. Also provided are skincare compositions comprising 3-(4-farnesyloxyphenyl)-propionic acid; and a processed oat ingredient selected from the group consisting of fermented oat, colloidal oat, oat extract, oat oil, and combinations thereof, wherein the composition is in the form of a solution, suspension, emulsion, lotion, cream, serum, gel, stick, spray, ointment, liquid wash, soap bar, shampoo, hair conditioner, paste, foam, powder, mousse, shaving cream, hydrogel, or film-forming product.
Provided are compositions and methods of treating sensitive skin with compositions comprising compounds having retinol-like activity. Also provided are methods of treating acne, wrinkles and/or lightening skin in a subject having a reaction condition or a history of a reaction condition with compositions comprising compounds having retinol-like activity.
Provided are skincare compositions comprising: an emollient; a viscosity increaser; an emulsifier; a humectant; and a compound having retinol-like activity. Also provided are methods of treating the skin, the method comprising applying topically to skin the skincare compositions. Also provided are skincare compositions comprising a) dimethicone; b) a viscosity increaser selected from the group consisting of polyacrylate crosspolymer-6, polyacrylate-13, sorbitan stearate, and combinations thereof; c) an emulsifier selected from the group consisting of sorbitan olivate, ceterayl olivate, and combinations thereof; d) glycerin; and e) a polar botanical extract of Acronychia acidula.
A61K 8/81 - Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
A61K 8/891 - Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
An absorbent article comprising a liquid permeable cover layer, an impervious barrier layer and an absorbent core between the cover layer and the barrier layer, wherein the barrier layer is impervious and biodegradable and comprises a kraft paper layer and a continuous resin coating; wherein the continuous resin coating is on the surface of the barrier layer disposed toward the absorbent core, and the continuous resin coating weight is from 10 to 18 g/m², and the continuous resin coating is an acrylic copolymer.
A61F 13/15 - Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the bodySupporting or fastening means thereforTampon applicators
A61F 13/472 - Sanitary towels, incontinence pads or napkins specially adapted for female use
A61F 13/514 - Backsheet, i.e. the impermeable cover or layer furthest from the skin
A61F 13/515 - Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the bodySupporting or fastening means thereforTampon applicators characterised by the outer layers of the pads characterised by the interconnection of the topsheet and the backsheet
A sprayable aerosol formulation includes a surfactant, a lipid, a solvent, a viscosity building ingredient, an active pharmaceutical ingredient (API) having antibiotic or anesthetic effect, and an aerosol propellant. The formulation may be substantially free of water.
A dispensing apparatus can be configured for dispensing material fluid from a container. The dispensing apparatus can include a collar, a fluid chamber, an actuator, and an air chamber. The collar can be configured to couple to a container defining a cavity configured to hold material. The fluid chamber can be fluid chamber coupled to the collar and configured to receive material from the cavity. The actuator can be movable relative to the collar from a first position to a second position. The actuator can be in fluid communication with the fluid chamber such that the actuator dispenses material from the fluid chamber as the actuator moves from the first position to the second position. The air chamber can be configured to urge the actuator from the second position to the first position.
B05B 11/10 - Pump arrangements for transferring the contents from the container to a pump chamber by a sucking effect and forcing the contents out through the dispensing nozzle
Systems, methods, and instrumentalities may be configured for managing infant health. An example system may communicate with a user device to collect and assess infant health metrics and parental usage. The system may configure a health trajectory for the infant by analyzing parental compliance and aggregate health data for generating an intervention data set. Interventions may be sent to the user device based on projected benefits and encouraging parental action. Health metrics may modify the health trajectory and interventions based on the infant's development and parental engagement. The system may monitor user compliance such that interventions are presented to maximize completion likelihood.
G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
The disclosure is directed to improved methods of treating minor pain in humans using a pharmaceutical dosage form comprising acetaminophen in admixture with naproxen.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
Systems, methods, non-transitory computer-readable mediums, and/or apparatuses are provided for determining a medication used by a patient. Label information for a medication may be determined. A source national drug code (NDC) associated with the medication may be determined. The source NDC may be validated. A product NDC and a normalized identifier may be determined. A brand name associated with the medication may be determined. One or more active ingredients associated with the brand name may be determined. A drug display name may be determined. The drug display name and active ingredient information for the one or more active ingredients may be displayed. A summary indicating an amount of the active ingredient may be displayed, for example, based on a medication diary.
G16H 70/40 - ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
Solid cleansing compositions including at least a first surfactant and a second surfactant in which the combined weight of the first surfactant and the second surfactant is at least about 60% by weight, based on the total weight of the solid cleansing composition. The solid cleansing composition can be in a powder form.
UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND (Ireland)
Inventor
Stamatas, Georgios N.
Sato, Takahiro
Oddos, Thierry
Hourihane, Jonathan
Irvine, Alan D.
Insel, Richard A.
Abstract
A method to predict a propensity of an infant to develop atopic dermatitis. The method includes observing the expression of S100A8/A9 on a skin area of an infant; comparing the expression to determined standard, wherein the determined standard is ascertained by measuring a level of the biomarker in a subject or pool of subjects who have demonstrated an absence of atopic dermatitis; and determining the propensity of an infant to develop atopic dermatitis, wherein an increase in the expression as compared to the determined standard indicates propensity of the infant to develop atopic dermatitis.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A tool that enables professional-level monitoring at home can provide patients with better access to expert advice regarding skin care. The tool may enable providing information about skin health to a patient's skin care specialist such that the most relevant information is emphasized and presented in a manner expected. The device may include a processor configured to receive a first skin image at a first time and a second skin image at a second time. The first and second time may be separated by a duration associated with a skin event. A plurality of skin characteristics may be determined from the first skin image and the second skin image. The processor may be configured to generate an analysis output and to transmit the analysis output to one or more receivers. The analysis output may include a synoptic representation of one or more of the plurality of skin characteristics.
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
Described are gummy dosage forms comprising tricalcium phosphate and a relaxing ingredient selected from Lemon balm extract, L-theanine, GABA, or mixtures thereof.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
24.
METHODS OF IMPROVING THE APPEARANCE OF SKIN AFFLICTED WITH ECZEMA
Provided is a method for improving the appearance of skin afflicted with eczema, the method comprising topically applying to skin afflicted with eczema a composition comprising lactic acid, optionally in combination with a volatile emollient and/or a processed oat ingredient.
The present invention provides a topical composition for pain relief containing a topical analgesic, as well as a volatile emollient and/or an absorbant. The topical composition is substantially free of volatile alcohol. The topical composition may be used to relieve pain in a user with sensitive skin. Additionally, the present invention includes methods of relieving pain in a user with sensitive skin. The methods include topically applying to an exterior skin portion of the user's body in need of pain treatment a composition including a topical analgesic, as well as a volatile emollient and/or an absorbant.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 47/46 - Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
26.
COMPOSITIONS SUITABLE FOR USE ON SKIN AFFLICTED WITH ECZEMA
A composition suitable for skin afflicted with eczema, the composition comprising: a. an alpha hydroxy acid; b. a volatile emollient; and c. a processed oat ingredient. A composition suitable for skin afflicted with eczema, the composition comprising: a. lactic acid; b. isododecane; and c. a processed oat ingredient selected from the group consisting of oat extract, colloidal oatmeal, oat oil and combinations thereof. Said compositions for use in the treatment of eczema.
A61K 47/46 - Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/085 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
27.
METHODS OF PROVIDING A COOLING SENSATION TO SKIN AFFLICTED WITH ECZEMA
Provided are methods of providing a cooling sensation to skin afflicted with eczema, the methods comprising topically applying to skin afflicted with eczema a composition comprising isododecane.
An emollient composition, a cleansing composition comprising the emollient composition, and a method of using a cleansing composition, the emollient composition including a blend of three different emollients, the emollients including an alkyl ester of myristate, an alkyl ester of cocoate, and a glycol ester of a fatty acid.
A method of predictively assessing skin sensitization of a personal care product formulation includes: calculating an upper confidence limit at a desired confidence level from multiple physical tests for skin sensitization of each of the ingredients in the personal care product formulation to define calculated skin sensitization values for the respective ingredients; applying at least one safety factor to at least one of the calculated skin sensitization values for the ingredients to define adjusted skin sensitization values for the respective ingredients; summing the adjusted skin sensitization values of the ingredients to define a total sensitization of the personal care product formulation; and comparing the total sensitization to a target product sensitization for the personal care product formulation. Such personal care product formulations do not require further testing and are capable of application to skin by users. Predictive systems and methods of preparing a personal care products are also disclosed.
G16H 50/00 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
A61K 8/18 - Cosmetics or similar toiletry preparations characterised by the composition
A cleansing composition in the form of a balm, comprising: a naturally occurring wax, wherein the wax comprises at least about 10% by weight of the cleansing composition of cetearyl alcohol, and at least about 6.5% by weight of the cleansing composition of either hydrogenated castor oil or cera alba or a mixture thereof; an oil, the oil being liquid at 20 °C, wherein at least about 50% by weight of the oil is caprylic/capric triglyceride or isopropyl myristate or a mixture thereof; a surfactant; and optionally an emollient, wherein the cleansing composition is substantially free of water.
The present invention provides a sustainable shampoo that includes alapha-olefin sulfonate; betaine; sodium hydrolyzed potato starch dodecenylsuccinate; and water. The sustainable shampoo is in the form of a solid structure. The sustainable shampoo is gentle and non-irritating. Recyclable or biodegradable paper packaging can be used preferably to reduce energy consumption. The present invention also provides a method for preparing the sustainable shampoo.
A method to assess the effectiveness of an oral fluid in the treatment of a subject suffering from an acute non-diarrhea illness, the method including: having the subject answer a self-rating questionnaire, where the subject selects a self-rating based on a 1 to 5 scale to create a baseline value; administering a first serving of the oral fluid to the subject; having the subject repeat the self-rating questionnaire at least one time over a 72-hour period after the first serving of the oral fluid is administered to create at least one additional value; and measuring a variation between the at least one additional value and the baseline value, where the variation indicates the effectiveness of the oral fluid in the treatment of the subject.
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 20/60 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
G06Q 30/02 - MarketingPrice estimation or determinationFundraising
A23L 2/00 - Non-alcoholic beveragesDry compositions or concentrates thereforPreparation or treatment thereof
33.
COMBINATION METHOD FOR TREATING OR PREVENTING CHILDHOOD ATOPIC DISEASE
The present application describes methods of treating or reducing the onset or occurrence of childhood atopic disease. In particular, it relates to an integrated solution that accounts for temporal and sequential administrations of three different and specific approaches for optimal effectiveness in treating or reducing the onset or occurrence of childhood atopic disease.
The present invention provides topical compositions comprising a combination ascorbic acid, caffeine, an inorganic salt, and water that are single aqueous phase compositions.
Described are solid anhydrous formulations suitable for lip care comprising: greater than 40% to less than 60% of an oil mixture comprising at least 70% of C8-10 fatty acids; greater than 15% to less than 25% of a wax mixture comprising at least 20% of esters of C20-24 fatty acids with glycerol; and greater than 20% to less than 40% of at least one butter, wherein the at least one butter comprises a natural butter which is solid at 20°C and has a melting point below 50°C., wherein all % are expressed in weight %.
C11C 3/08 - Fats, oils or fatty acids obtained by chemical modification of fats, oils or fatty acids, e.g. by ozonolysis by esterification of fats or fatty oils with fatty acids
A61K 8/92 - Oils, fats or waxesDerivatives thereof, e.g. hydrogenation products
A61Q 1/04 - Preparations containing skin colorants, e.g. pigments for lips
C11C 3/08 - Fats, oils or fatty acids obtained by chemical modification of fats, oils or fatty acids, e.g. by ozonolysis by esterification of fats or fatty oils with fatty acids
39.
SYSTEMS, METHOD, AND APPARATUS FOR PROVIDING PERSONALIZED MEDICAL DATA
A device disclosed herein may be used for providing personal medical data. The device may comprise a memory and/or a processor. The processor may be configured to perform a number of actions. A graphic of a human body may be displayed. A user input associated with a location on the graphic of a human body may be received from a user. An organ context may be determined based on the location on the graphic of the human body. A biomarker related to the organ context may be determined. Contextualized health data that indicates a significance of the biomarker in relation to the organ context may be generated. In response to the user input, the device may display the contextualized health data, a recommended action, and an indication of an amount of time that the user's life may be extended by the user performing the recommended action.
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 10/65 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records stored on portable record carriers, e.g. on smartcards, RFID tags or CD
G16H 20/60 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
G16H 30/00 - ICT specially adapted for the handling or processing of medical images
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
An otoscope apparatus having an objective lens configured to focus light from an object, a field lens positioned parallel to the objective lens along an optical axis, a first aperture and a second aperture positioned, respectively, at a distal end and a proximal end of the objective lens, and a third aperture positioned at a distal end of the field lens. The otoscope apparatus is adapted to be releasably attached to a camera of a smart device. The otoscope apparatus may capture a picture or video of the outer ear, the middle ear, and/or the ear canal of a patient utilizing the camera of the smart device. Such a picture or video of the outer ear, the middle ear, and/or the ear canal may be sent to a remote healthcare professional for diagnosis of an ear infection.
A61B 1/227 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for ears, i.e. otoscopes
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
A method to predict a propensity of an individual to develop atopic dermatitis is disclosed. The method, which involves use of biological markers, can also be used to evaluate the efficacy of a composition to treat atopic dermatitis. The markers include hBD1, IL1RA, IL36g and S100A8/9, various skin microbe species and total amino acid content.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
A teething apparatus includes a water-resistant housing containing a controller and a power source and communication means and a plurality of sensors in communication with the surface of the housing arranged and configured to detect at least pH and at least one volatile organic compound. Each of the plurality of sensors is in data communication with the controller and the controller is capable of communication with an external device via communication means. The apparatus may be a component of a larger system and may be used in a method including the steps of providing a teething apparatus to an oral cavity of an infant, establishing a data connection between the teething apparatus and a remote device, and relaying information from the teething apparatus to the remote device, the information comprising the qualitative measurement of one or more volatile organic compounds and the quantitative value of pH in the oral cavity.
An improved customizable dosage form comprising a substrate, such as a tablet core, that has one or more distinct, discreet cavities on its exterior surface, wherein simethicone is deposited into at least one of the cavities.
The present invention relates to curable compositions useful in the manufacture of absorbent films or absorbent film products. Methods of using and manufacturing the compositions also disclosed.
C08F 2/48 - Polymerisation initiated by wave energy or particle radiation by ultraviolet or visible light
A61L 15/22 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
A61L 15/60 - Liquid-swellable gel-forming materials, e.g. super-absorbents
C08L 51/00 - Compositions of graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bondsCompositions of derivatives of such polymers
An improved customizable dosage form comprising a substrate, such as a tablet core, that has one or more distinct, discreet cavities on its exterior surface, wherein simethicone is deposited into at least one of the cavities.
Provided are compositions suitable for skin care. Certain compositions comprise a. one or more a C20-24 fatty alcohols; b. one or more anionic surfactants; c. one or more thickening polysaccharides comprising succinoglycan; d. one or more emollients comprising at least one natural butter having a natural butter which is solid at 20°C and has a melting point below 50°C; and e. about 50 to about 95 wt.% of water by weight of the total composition, wherein the composition is in the form of an emulsion.
Provided are compositions suitable for skin care. Certain compositions comprise a. one or more a C20‐24 fatty alcohols; b. one or more anionic surfactants; c. one or more thickening polysaccharides comprising succinoglycan; d. one or more emollients comprising at least one natural butter having a natural butter which is solid at 20°C and has a melting point below 50°C; and e. about 50 to about 95 wt.% of water by weight of the total composition, wherein the composition is in the form of an emulsion.
Provided are methods of quantifying miRNA in skin, the method comprising: applying a swellable microprotrusion array to a region of skin to absorb interstitial fluid; removing the microprotrusion array; recovering miRNA from the interstitial fluid absorbed into the microprotrusion array; and quantifying the miRNA. Also provided are methods of monitoring epigenetic changes in skin using a swellable microprotrusion array.
Provided are methods of quantifying miRNA in skin, the method comprising: applying a swellable microprotrusion array to a region of skin to absorb interstitial fluid; removing the microprotrusion array; recovering miRNA from the interstitial fluid absorbed into the microprotrusion array; and quantifying the miRNA. Also provided are methods of monitoring epigenetic changes in skin using a swellable microprotrusion array.
JOHNSON & JOHNSON CONSUMER INC. (A DELAWARE CORPORATION) (USA)
Inventor
Kyungrok, Min
Fourre, Tara
Abstract
The present invention relates to methods and kits for providing high throughput quantitative analysis of impact (e.g., by application of materials which affect ¨ positively and/or negatively ¨ microbial species) on human microbiome.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Provided are compositions and methods for oral delivery to an infant of a composition containing Bifidobacterium. The composition may be pre-loaded into or placed directly onto an artificial nipple or pacifier and may also be applied directly to the skin of a caregiver and/or to one of the gums, teeth or cheek of the infant. The compositions of the invention are provided in soft gel fill, dissolvable or disintegrable tablet or powder or semisolid forms and are stable for at least 24 months when stored at 25°C and 65% relative humidity.
BifidobacteriumBifidobacterium. The composition may be pre-loaded into or placed directly onto an artificial nipple or pacifier and may also be applied directly to the skin of a caregiver and/or to one of the gums, teeth or cheek of the infant. The compositions of the invention are provided in soft gel fill, dissolvable or disintegrable tablet or powder or semisolid forms and are stable for at least 24 months when stored at 25°C and 65% relative humidity.
Inria (Institut national de recherche en informatique et en automatique) (France)
JOHNSON & JOHNSON CONSUMER INC. (USA)
Inventor
Descombes, Xavier
Lboukili, Imane
Oddos, Thierry
Stamatas, Georgios N.
Abstract
Methods for non-invasive or minimally invasive assessment of epithelial tissue structure are disclosed. Digital imaging and processing are used to identify cell locations. More specifically, an automated algorithm that may be used to identify epithelial tissue structure, and/or to specify the coordinates/locations of cells in the epithelial tissue structure, through non-invasive or minimally invasive imaging, and use of this information to extract values of epithelial structure related parameters are disclosed.
G06V 10/74 - Image or video pattern matchingProximity measures in feature spaces
G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
54.
SYSTEM AND METHOD FOR IN SITU MEASURING AND COLLECTING SAMPLES OF ANALYTE CONCENTRATION IN BODILY FLUIDS
A system and related methods include a durable component, an indicator component including an indicator zone comprising at least one colorimetric analyte sensing element, at least one moisture sensor, and a fluid collection reservoir. The durable component contains at least one spectrophotometer, a computing system, and means for electronic communication between the computing system and at least one external device. The indicator component includes at least one colorimetric analyte sensing element and a fluid transport layer in fluid communication with the indicator zone, and it is arranged and configured for attachment to the durable component. In addition, the moisture sensor is arranged and configured to communicate the presence of moisture to initiate a predetermined delay in measuring the concentration of at least one analyte. The fluid collection reservoir is releasable from at least one of the indicator components and the durable component at a predetermined breaking point for clinical analysis.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
55.
ANALYSIS AND CHARACTERIZATION OF EPITHELIAL TISSUE STRUCTURE
Methods for non-invasive or minimally invasive assessment of epithelial tissue structure are disclosed. Digital imaging and processing are used to identify cell locations. More specifically, an automated algorithm that may be used to identify epithelial tissue structure, and/or to specify the coordinates/locations of cells in the epithelial tissue structure, through non-invasive or minimally invasive imaging, and use of this information to extract values of epithelial structure related parameters are disclosed.
G06V 10/26 - Segmentation of patterns in the image fieldCutting or merging of image elements to establish the pattern region, e.g. clustering-based techniquesDetection of occlusion
G06V 10/42 - Global feature extraction by analysis of the whole pattern, e.g. using frequency domain transformations or autocorrelation
G06V 10/44 - Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersectionsConnectivity analysis, e.g. of connected components
G06V 10/75 - Organisation of the matching processes, e.g. simultaneous or sequential comparisons of image or video featuresCoarse-fine approaches, e.g. multi-scale approachesImage or video pattern matchingProximity measures in feature spaces using context analysisSelection of dictionaries
G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
A system and related methods include a durable component, an indicator component including an indicator zone comprising at least one colorimetric analyte sensing element, at least one moisture sensor, and a fluid collection reservoir. The durable component contains at least one spectrophotometer, a computing system, and means for electronic communication between the computing system and at least one external device. The indicator component includes at least one colorimetric analyte sensing element and a fluid transport layer in fluid communication with the indicator zone, and it is arranged and configured for attachment to the durable component. In addition, the moisture sensor is arranged and configured to communicate the presence of moisture to initiate a predetermined delay in measuring the concentration of at least one analyte. The fluid collection reservoir is releasable from at least one of the indicator components and the durable component at a predetermined breaking point for clinical analysis.
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
The present invention provides methods of diagnosing and treating fast aging skin, especially in young subjects, by measuring and/or adjusting a property selected from cell proliferation rate, NFKB1 gene expression, CDKN1A gene expression, CDKN2A gene expression, CEBPB gene expression, and combinations thereof.
The present invention provides methods of diagnosing and treating fast aging skin, especially in young subjects, by measuring and/or adjusting a property selected from cell proliferation rate, NFKB1 gene expression, CDKN1A gene expression, CDKN2A gene expression, CEBPB gene expression, and combinations thereof.
Methods of screening types and amounts of antioxidants, determining effectiveness of the antioxidants, preparing compositions including effective amounts of the antioxidants (and uses thereof), and reducing the formation of clogged pores and acne are provided. Methods include the formation of test samples in a solvent system (optionally with one or more bacterial metabolites) including one or more antioxidants in amounts to be evaluated for effectiveness against control samples without antioxidants. The samples are exposed to an oxidation-inducing element (such as UVA rays) and the amount of oxidation byproduct is evaluated. Based on the effectiveness of the antioxidant(s) in the amount(s) tested, formulations can be prepared to include the one or more antioxidants in the amount(s) effective to reduce oxidation of the oxidizable component, preventing and reducing the formation of the oxidation byproduct. The formulations can be used, for example, to reduce the formation of clogged pores and acne.
Methods of screening types and amounts of antioxidants, determining effectiveness of the antioxidants, preparing compositions including effective amounts of the antioxidants (and uses thereof), and reducing the formation of clogged pores and acne are provided. Methods include the formation of test samples in a solvent system (optionally with one or more bacterial metabolites) including one or more antioxidants in amounts to be evaluated for effectiveness against control samples without antioxidants. The samples are exposed to an oxidation-inducing element (such as UVA rays) and the amount of oxidation byproduct is evaluated. Based on the effectiveness of the antioxidant(s) in the amount(s) tested, formulations can be prepared to include the one or more antioxidants in the amount(s) effective to reduce oxidation of the oxidizable component, preventing and reducing the formation of the oxidation byproduct. The formulations can be used, for example, to reduce the formation of clogged pores and acne.
An apparatus for non-invasively sampling and monitoring biomarkers for assessing health, well-being and/or performance of a human subject includes a substrate, a central collecting region disposed on at least a portion of an upper surface of the substrate, multiple analytic reservoirs disposed on at least a portion of the upper surface of the substrate and spaced laterally from the central collecting region, multiple connecting channels adapted for conveying a biofluid, containing biomarkers obtained from the human subject, from the central collecting region to the respective analytic reservoirs, and multiple valves, each of the valves disposed in-line between the central collecting region and a corresponding one of the analytic reservoirs.
A sensor apparatus for measuring trans-epithelial water loss includes a first sensor device and at least a second sensor device stacked on and vertically aligned with the first sensor device, each sensor device including first and second vertically aligned heating/sensing elements respectively, each being separated from one another by a first distance and affixed within a first open frame, and including respective contacts providing electrical connection thereto. Each of the heating/sensing elements is configured to allow a gas/vapor mixture being measured to flow freely through the sensor apparatus.
The present invention provides sunscreen composition comprising a hydrophobically modified polyurethane, a viscosity increasing polymer, and glyceryl stearate. This composition has surprisingly light aesthetics while providing excellent UV protection.
A61K 8/895 - Polysiloxanes containing silicon bound to unsaturated aliphatic groups, e.g. vinyl dimethicone
A61K 8/81 - Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
Provided are methods of determining effectiveness of face treatments comprising: providing a front-facing image of the face prior to use of the treatment; identifying a y-axis of the face, wherein the y-axis is defined by a line connecting the center position of the chin of the face through the center of the face; identifying an x-axis of the face, wherein the x-axis is defined by a line that is positioned at a 90-degree angle from the y-axis and goes through the center of the chin of the face; selecting a facial landmark; identifying a facial landmark line, wherein the facial landmark line is defined by a line connecting the center position of the chin of the face to the facial landmark; measuring the angle between the x-axis and the facial landmark line; carrying out the treatment on the face; providing a front-facing image of the face after the treatment.
Provided are methods of determining effectiveness of face treatments comprising: providing a front-facing image of the face prior to use of the treatment; identifying a y-axis of the face, wherein the y-axis is defined by a line connecting the center position of the chin of the face through the center of the face; identifying an x-axis of the face, wherein the x-axis is defined by a line that is positioned at a 90-degree angle from the y-axis and goes through the center of the chin of the face; selecting a facial landmark; identifying a facial landmark line, wherein the facial landmark line is defined by a line connecting the center position of the chin of the face to the facial landmark; measuring the angle between the x-axis and the facial landmark line; carrying out the treatment on the face; providing a front-facing image of the face after the treatment.
The invention relates to a coated famotidine particle having at least a core and a coating layer, wherein the particle core comprises famotidine, a first filler and a first binder; and wherein the coating layer is substantially free from famotidine and comprises a second filler and a second binder. The invention also relates to solid dosage forms comprising said coated famotidine particle, and the use of the coated famotidine particle for treating a subject suffering from a disease or disorder in the gastrointestinal tract.
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
67.
A PHARMACEUTICAL COMPOSITION COMPRISING FAMOTIDINE
The invention relates to a coated famotidine particle having at least a core and a coating layer, wherein the particle core comprises famotidine, a first filler and a first binder; and wherein the coating layer is substantially free from famotidine and comprises a second filler and a second binder. The invention also relates to solid dosage forms comprising said coated famotidine particle, and the use of the coated famotidine particle for treating a subject suffering from a disease or disorder in the gastrointestinal tract.
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
68.
METHODS OF USING COMPOSITIONS COMPRISING AN ICELAND MOSS EXTRACT
Provided are methods of reducing pain or itch, the method comprising administering to a patient in need thereof a therapeutically effective dose of a composition comprising a non-polar extract of Iceland moss.
Concentrated compositions, methods of using concentrated compositions, kits including concentrated compositions, and diluted forms of the concentrated compositions, which can be used to provide a benefit to the skin of the user.
A61K 8/55 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing phosphorus
A61K 8/81 - Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
A61K 8/92 - Oils, fats or waxesDerivatives thereof, e.g. hydrogenation products
Provided are methods of reducing pain or itch, the method comprising administering to a patient in need thereof a therapeutically effective dose of a composition comprising a non-polar extract of Iceland moss.
Umbilical cord sensors for monitoring biomarkers and other information associated with an umbilical cord are provided. Some exemplary embodiments of sensors include both an outer body and expandable inner body, with both bodies being disposed at least partially around an umbilical cord, the inner body being disposed within the outer body. The expandable inner body defines a receiving channel for receiving the umbilical cord, and is selectively expanded and contracted to engage and disengage with the umbilical cord. One or more biosensors and/or one or more sampling features can be included as part of the umbilical cord sensors, with the biosensors measuring one or more parameters and the sampling features obtaining one or more biomarkers associated with the umbilical cord. Exemplary methods of using umbilical cord sensors during the childbirth process are also provided, among other sensor configurations and methods of use.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
Concentrated compositions, methods of using concentrated compositions, kits including concentrated compositions, and diluted forms of the concentrated compositions, which can be used to provide a benefit to the skin of the user.
A61K 8/55 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing phosphorus
A61K 8/81 - Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
A61K 8/92 - Oils, fats or waxesDerivatives thereof, e.g. hydrogenation products
Umbilical cord sensors for monitoring biomarkers and other information associated with an umbilical cord are provided. Some exemplary embodiments of sensors include both an outer body and expandable inner body, with both bodies being disposed at least partially around an umbilical cord, the inner body being disposed within the outer body. The expandable inner body defines a receiving channel for receiving the umbilical cord, and is selectively expanded and contracted to engage and disengage with the umbilical cord. One or more biosensors and/or one or more sampling features can be included as part of the umbilical cord sensors, with the biosensors measuring one or more parameters and the sampling features obtaining one or more biomarkers associated with the umbilical cord. Exemplary methods of using umbilical cord sensors during the childbirth process are also provided, among other sensor configurations and methods of use.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
74.
ALIGMENT OF A CLIP-ON MEDICAL DEVICE TO A SMART DEVICE CAMERA
A smart device may assist a user in aligning an otoscope of an otoscope clip device with a camera of the smart device. A model identification may be determined. The model identification may indicate a model associated with the smart device. An alignment image may be determined using the model identification. The alignment image may be displayed on the display of the smart device.
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances
A61B 1/06 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with illuminating arrangements
A61B 1/227 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for ears, i.e. otoscopes
75.
ALIGNMENT OF A CLIP-ON MEDICAL DEVICE TO A SMART DEVICE CAMERA
A smart device may assist a user in aligning an otoscope of an otoscope clip device with a camera of the smart device. A model identification may be determined. The model identification may indicate a model associated with the smart device. An alignment image may be determined using the model identification. The alignment image may be displayed on the display of the smart device.
A61B 1/227 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for ears, i.e. otoscopes
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances
A61B 1/06 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with illuminating arrangements
76.
DEVICE AND METHOD FOR CONTINUOUS EVEN APPLICATION OF COMPOSITION TO SKIN
A device and method for selectively applying a cosmetic composition to a treatment surface (e.g., skin) to alter an aesthetic appearance of the skin. The device (100) includes a detector (110) obtaining image data corresponding to an image of an area of skin and an applicator (120) applying the composition to the skin. The applicator (120) is aligned to apply the composition to a location within the imaged area of skin. The device analyzes the image data and selectively applies the composition to the location when a reflectance value of the area of skin is (i) less than a reflectance value of a selected tone, and (ii) greater than a reflectance value of the location. The reflectance value of the selected tone may be generated based on image data corresponding to a region of skin adjacent to the area of skin. The device and method aim to reduce appearance of undesirable skin artifacts and enhance the aesthetic appearance of skin while limiting the need for the application of a continuous layer of cosmetic composition.
Provided are cleansing compositions comprising: (a) cocamidopropyl betaine, wherein the cocamidopropyl betaine has an average molecular weight of at least about 355 g/mol; (b) from greater than about 0 wt.-% to about 1 wt-% of a fatty acid; and (c) water. Also provided are methods of using the same.
A device and method for selectively applying a cosmetic composition to a treatment surface (e.g., skin) to alter an aesthetic appearance of the skin. The device (100) includes a detector (110) obtaining image data corresponding to an image of an area of skin and an applicator (120) applying the composition to the skin. The applicator (120) is aligned to apply the composition to a location within the imaged area of skin. The device analyzes the image data and selectively applies the composition to the location when a reflectance value of the area of skin is (i) less than a reflectance value of a selected tone, and (ii) greater than a reflectance value of the location. The reflectance value of the selected tone may be generated based on image data corresponding to a region of skin adjacent to the area of skin. The device and method aim to reduce appearance of undesirable skin artifacts and enhance the aesthetic appearance of skin while limiting the need for the application of a continuous layer of cosmetic composition.
The present invention is directed to an orally disintegrable multi-layered particle comprising a hydrophobic core containing simethicone, a hydrophilic surfactant layer, and a hydrophilic disintegrant layer; wherein said hydrophilic surfactant layer is located between the hydrophobic core and the hydrophilic disintegrant layer; and orally disintegrable solid dosage forms comprising said multi-layered particle, and related processes.
The present invention is directed to an orally disintegrable multi-layered particle comprising a hydrophobic core containing simethicone, a hydrophilic surfactant layer, and a hydrophilic disintegrant layer; wherein said hydrophilic surfactant layer is located between the hydrophobic core and the hydrophilic disintegrant layer; and orally disintegrable solid dosage forms comprising said multi-layered particle, and related processes.
Provided are compositions methods of preventing, delaying or ameliorating atopic dermatitis in a breastfed infant having an increased risk of developing an atopic disease, the method comprising administering a composition comprising administering a Bifidobacterium to the breastfed infant.
An oral fluids sample collection method and apparatus includes a shield having a first face and a second face; an elastomeric nipple having an outer surface and defining a nipple interior extending from the first face of the shield; and a reservoir component extending from the second face of the shield comprising a reservoir having a reservoir interior. These elements are interconnected by a plurality of fluid conduit/valve combinations, including a first combination permitting flow from the nipple interior to an atmospheric vent port disposed on an exterior surface of the oral fluids collection device; a second combination permitting flow from the reservoir interior to the nipple interior; and a third combination permitting flow from a collection port disposed on the outer surface of the nipple to an exit port in the reservoir interior.
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
An oral fluids sample collection method and apparatus includes a shield having a first face and a second face; an elastomeric nipple having an outer surface and defining a nipple interior extending from the first face of the shield; and a reservoir component extending from the second face of the shield comprising a reservoir having a reservoir interior. These elements are interconnected by a plurality of fluid conduit/valve combinations, including a first combination permitting flow from the nipple interior to an atmospheric vent port disposed on an exterior surface of the oral fluids collection device; a second combination permitting flow from the reservoir interior to the nipple interior; and a third combination permitting flow from a collection port disposed on the outer surface of the nipple to an exit port in the reservoir interior.
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
Provided are methods and compositions suitable for treating acne, disrupting a biofilm, and/or killing bacteria contained in a biofilm. Certain methods comprise contacting skin in need of such treatment with a composition comprising two alpha hydroxy acids and a polyhydroxy acid. Certain other methods comprise applying to a surface having a biofilm a composition comprising a first alpha hydroxy acid, a second alpha hydroxy acid, and a polyhydroxy acid. Certain compositions comprise a. about 0.1 wt.% to about 7.5 wt.% glycolic acid; b. about 0.1 wt.% to about 5 wt.% gluconolactone; c. about 0.1 wt.% to about 5 wt.% mandelic acid d. a glycol; e. a salt-tolerant thickening polymer, wherein the total amount of glycolic acid, gluconolactone and mandelic acid is less than about 15 wt.% of the total composition.
A61K 8/81 - Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
JOHNSON & JOHNSON CONSUMER INC. (A DELAWARE CORPORATION) (USA)
Inventor
Zhuk, Aliaksandr
Geonnotti, Anthony
Miller, Dara
Li, Jennifer
Batchvarova, Nikoleta
Comito, Nicole
Abstract
Provided are methods and compositions suitable for treating acne, disrupting a biofilm, and/or killing bacteria contained in a biofilm. Certain methods comprise contacting skin in need of such treatment with a composition comprising two alpha hydroxy acids and a polyhydroxy acid. Certain other methods comprise applying to a surface having a biofilm a composition comprising a first alpha hydroxy acid, a second alpha hydroxy acid, and a polyhydroxy acid. Certain compositions comprise a. about 0.1 wt.% to about 7.5 wt.% glycolic acid; b. about 0.1 wt.% to about 5 wt.% gluconolactone; c. about 0.1 wt.% to about 5 wt.% mandelic acid d. a glycol; e. a salt-tolerant thickening polymer, wherein the total amount of glycolic acid, gluconolactone and mandelic acid is less than about 15 wt.% of the total composition.
A61K 8/81 - Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
JOHNSON & JOHNSON CONSUMER INC. (A DELAWARE CORPORATION) (USA)
Inventor
Edgar, Albert Durr
Higgins, Laura
Abstract
A device and method for selectively applying a composition to a treatment surface (e.g., skin) to alter an aesthetic appearance of the skin in the undereye region of the face. The device includes an applicator applying the composition to the skin, and a detector obtaining image data corresponding to an image of an area of skin. The device generates a target reflectance value based on the image data and past image data. The target reflectance value is higher than reflectance of at least half of areas corresponding to the image data and past image data. The device determines a desired level of reflectance modification for a location within the area of skin imaged by comparing image data corresponding to reflectance of the location to the target reflectance value, and directs the applicator to selectively apply the composition to the location based on the desired level of reflectance modification.
e.g.e.g., skin) to alter an aesthetic appearance of the skin in the undereye region of the face. The device includes an applicator applying the composition to the skin, and a detector obtaining image data corresponding to an image of an area of skin. The device generates a target reflectance value based on the image data and past image data. The target reflectance value is higher than reflectance of at least half of areas corresponding to the image data and past image data. The device determines a desired level of reflectance modification for a location within the area of skin imaged by comparing image data corresponding to reflectance of the location to the target reflectance value, and directs the applicator to selectively apply the composition to the location based on the desired level of reflectance modification.
A solid cleansing composition comprising a (I) first and a (II) second phase; wherein the (I) first phase comprises a mixture of ingredients including (a) a solid surfactant, (b) a disintegration agent and (c) a lubricant; the (2) second phase comprising (d) a superabsorbent polymer and (e) a binder.
A device for attaching an optical element, such as an otoscope, to a smart phone for diagnosing and/or identifying problems of an outer ear, a middle ear, and/or an ear cannal of a patient. The device may comprise a main body. The main body may comprise an aperture and a first engagement member configured to engage with a second engagement structure that belongs to the optical element. A first surface may be connected to the main body and configured may be to contact a first smart phone surface. A piston may be provided that may comprises a second surface that may be parallel to the first surface and may be configured to contact a second smart phone surface. A threaded knob may be provided and may be connected to the piston through the aperture.
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
G02B 7/02 - Mountings, adjusting means, or light-tight connections, for optical elements for lenses
A61B 1/227 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for ears, i.e. otoscopes
A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
93.
DEVICE AND METHOD FOR CONTROLLING TREATMENT FOR A SKIN CONDITION USING A TRACER
A device and method for treating a skin condition is provided. The device may include an applicator arrangement applying a composition to skin. The composition comprising an active ingredient for treating the skin condition and a tracer. The device may also include a detector arrangement obtaining image data corresponding to an image of an area of skin. The device may further include a processing arrangement analyzing the image data to determine whether an artifact corresponding to the skin condition is detected at a location within the imaged area of the skin and to determine an amount of the tracer detected from the location, the processing arrangement directing the applicator arrangement to apply the composition to the location when the artifact is detected and the amount of the tracer is less than a predetermined threshold level.
JOHNSON & JOHNSON CONSUMER INC. (A DELAWARE CORPORATION) (USA)
Inventor
Edgar, Albert Durr
Abstract
A device and method for treating a skin condition is provided. The device may include an applicator arrangement applying a composition to skin. The composition comprising an active ingredient for treating the skin condition and a tracer. The device may also include a detector arrangement obtaining image data corresponding to an image of an area of skin. The device may further include a processing arrangement analyzing the image data to determine whether an artifact corresponding to the skin condition is detected at a location within the imaged area of the skin and to determine an amount of the tracer detected from the location, the processing arrangement directing the applicator arrangement to apply the composition to the location when the artifact is detected and the amount of the tracer is less than a predetermined threshold level.
JOHNSON & JOHNSON CONSUMER INC. (A DELAWARE CORPORATION) (USA)
Inventor
Knecht, Max Hunter
Anton, Stephen
Coyle, Sean James
Wald, Nathan
Small, Eleanor F.
Kaminsky, Nicole
Abstract
A device for attaching an optical element, such as an otoscope, to a smart phone for diagnosing and/or identifying problems of an outer ear, a middle ear, and/or an ear cannal of a patient. The device may comprise a main body. The main body may comprise an aperture and a first engagement member configured to engage with a second engagement structure that belongs to the optical element. A first surface may be connected to the main body and configured may be to contact a first smart phone surface. A piston may be provided that may comprises a second surface that may be parallel to the first surface and may be configured to contact a second smart phone surface. A threaded knob may be provided and may be connected to the piston through the aperture.
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances
A61B 1/227 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for ears, i.e. otoscopes
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G02B 7/02 - Mountings, adjusting means, or light-tight connections, for optical elements for lenses
JOHNSON & JOHNSON CONSUMER INC. (A DELAWARE CORPORATION) (USA)
Inventor
Howard, Matthew A.
Hopson, Peyton
Sinsel, Joshua
Bean, Anthony
Dave, Vipul
Abstract
An improved customizable dosage form comprising a substrate, such as a tablet core, that has two or more distinct, discrete cavities on opposing sides of its exterior surface; and/or two or more distinct, discrete cavities on a first side of its exterior surface and an identification feature on a second opposing side of its exterior surface. A process for making such a customizable dosage form wherein one or more active ingredients and inactive ingredients such as colors, flavors and/or sensates are deposited into at least one of the cavities.
A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/4402 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
An improved customizable dosage form comprising a substrate, such as a tablet core, that has two or more distinct, discrete cavities on opposing sides of its exterior surface; and/or two or more distinct, discrete cavities on a first side of its exterior surface and an identification feature on a second opposing side of its exterior surface. A process for making such a customizable dosage form wherein one or more active ingredients and inactive ingredients such as colors, flavors and/or sensates are deposited into at least one of the cavities.
A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/4402 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
JOHNSON & JOHNSON CONSUMER INC. (A DELAWARE CORPORATION) (USA)
Inventor
Bruning, Elizabeth
Capone, Kimberly
Oak, Alpana
Geonnotti, Anthony Robert
Ekman-Gunn, Euen Thomas
Kirchner, Frank J.
Walters, Russel
Sun, Frank C.
Abstract
This invention relates to methods and compositions for inhibiting the transmission of enveloped viruses, which entails applying a composition containing a high molecular weight hydrophobically-modified polymer to an infectable or ingestible surface that may contain viruses and wherein said anti-viral composition is substantially free of surfactant having an HLB greater than about 12.
JOHNSON & JOHNSON CONSUMER INC. (A DELAWARE CORPORATION) (USA)
Inventor
Bruning, Elizabeth
Capone, Kimberly
Gandolfi, Lisa
Geonnotti, Anthony Robert
Ekman-Gunn, Euen Thomas
Johnson, Diana Roshek
Kirchner, Frank J.
Moses, Selina
Santora, Delores
Walters, Russel
Sun, Frank C.
Abstract
This invention relates to methods and compositions for inhibiting the transmission of influenza viruses, which entails applying a composition containing a polyalkylene glycol compound to an infectable or ingestible surface that may contain viruses. It further relates to methods and compositions for inhibiting the transmission of influenza and other enveloped viruses, which entails applying a composition containing a polyalkylene glycol compound and a low molecular weight hydrophobically-modified polymer to an infectable or ingestible surface that may contain viruses.
This invention relates to methods and compositions for inhibiting the transmission of enveloped viruses, which entails applying a composition containing a low molecular weight hydrophobically-modified polymer to an infectable or ingestible surface that may contain viruses, wherein said compositions further comprise less than about 9% by weight of surfactant having an HLB of greater than 12.
patents
